Acquisition of APIRx slide image

Acquisition of APIRx

For personal use only Cannabinoid Chewing Gums and chewable tablets for Treatment of Addiction APIRX has multiple patents for cannabinoid based drug candidates designed for treatment of addiction to different drug classes. Marijuana addiction CheWell for Cannabis Dependence APIRX has a patented CBD chewable tablet high-bioavailability that can be used in treatment of marijuana addiction. Cannabis dependence is predicted to to be the fastest growing segment of drug dependence market. Preliminary data suggest a possible beneficial impact of CBD on mitigating the craving effect of cannabis; while a case report has shown positive outcomes for one patient treated with CBD during the withdrawal and relapse phase of cannabis dependence. Pre-IND with FDA is pending. 20311 Smoking cessation CanQuit - Nicotine Addiction APIRX patented chewing gum that combines cannabinoids with reducing doses of nicotine. OTC product to be trialled for effectiveness against existing nicotine medicated chewing gums. A more-effective and cost effective cannabinoid + nicotine gum may disrupt the incumbent global nicotine gum market, which had sales of US$ 5.2B in 2020. By combining nicotine and cannabinoids, patented APIRX product CanQuit is designed to better assist addicted smokers to quit smoking. Opioid addiction CanQuit O - Opioid Addiction APIRX patented chewing gum that combines cannabinoids with opioid agonists and/or antagonists. A prescription product to combat the opioid addiction for which the annual market size in the United States alone is expected to reach US$ 64B by 2028. The act of mastication (chewing) aids neuroprotection, has an analgesic and anti-anxiety effect, which should also assist to suppress opioid cravings. Incannex Opioid use disorder addressable market US$ 64B* Nicotine chewing gum market sales of US$ 5.2B" in 2020 MCGs for nicotine addiction already accepted in the real world. Lead Assets * Frost & Sullivan Market Report as commissioned by APIRX; and other publicly available information ** https://www.imarcgroup.com/nicotine-gum-market Shareholder Presentation 00 16
View entire presentation